KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Depreciation & Amortization (CF) (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Depreciation & Amortization (CF) for 16 consecutive years, with $3.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 23.97% to $3.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $11.4 million, a 10.62% increase, with the full-year FY2025 number at $11.4 million, up 10.97% from a year prior.
  • Depreciation & Amortization (CF) was $3.3 million for Q4 2025 at Halozyme Therapeutics, up from $2.7 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $3.3 million in Q4 2025 to a low of $700000.0 in Q1 2021.
  • A 5-year average of $2.1 million and a median of $2.6 million in 2024 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): dropped 22.22% in 2021, then soared 230.15% in 2022.
  • Halozyme Therapeutics' Depreciation & Amortization (CF) stood at $776000.0 in 2021, then skyrocketed by 230.15% to $2.6 million in 2022, then grew by 15.07% to $2.9 million in 2023, then fell by 10.01% to $2.7 million in 2024, then grew by 23.97% to $3.3 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's Depreciation & Amortization (CF) are $3.3 million (Q4 2025), $2.7 million (Q3 2025), and $2.7 million (Q2 2025).